NIMble innovation—a networked model for public antibiotic trials
Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical...
Main Authors: | Rebecca E Glover, PhD, Andrew C Singer, PhD, Adam P Roberts, PhD, Claas Kirchhelle, PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | The Lancet Microbe |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666524721001828 |
Similar Items
-
New antibiotic replacements as growth and health promoters
by: Hashemi SR (PhD), et al.
Published: (2012-01-01) -
Exchange of Modular Components Improves Success of Debridement, Antibiotics, and Implant Retention
by: Karin Svensson, MD, PhD, et al.
Published: (2020-12-01) -
Nonprescription fish antibiotics:Why Is This Important?
by: Eugenia Popescu Roberts, DDS, et al.
Published: (2022-01-01) -
Public Health and Rare Diseases: Oxymoron No More
by: Rodolfo Valdez, PhD, et al.
Published: (2016-01-01) -
Book Review: Innovations in Health Services Delivery: The Corporatization of Public Hospitals
by: Gary L. Filerman Ph.D.
Published: (2004-05-01)